logo_ProQR-150x150.png
ProQR Announces Webcast Presentation at the 2024 Cantor Global Healthcare Conference
September 10, 2024 16:30 ET | ProQR Therapeutics N.V.
LEIDEN, Netherlands & CAMBRIDGE, Mass., Sept. 10, 2024 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA...
logo_ProQR-150x150.png
ProQR Announces Second Quarter 2024 Operating and Financial Results
August 08, 2024 07:00 ET | ProQR Therapeutics N.V.
AX-0810 program targeting NTCP for cholestatic diseases and AX-1412 program targeting B4GALT1 for cardiovascular diseases advancing to the clinic in late 2024/early 2025 with translational data and...
logo_ProQR-150x150.png
ProQR Announces Presentation on its Axiomer™ RNA Editing Technology at RNA Editing Summit
June 18, 2024 08:00 ET | ProQR Therapeutics N.V.
LEIDEN, Netherlands & CAMBRIDGE, Mass., June 18, 2024 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA...
logo_ProQR-150x150.png
ProQR Announces First Quarter 2024 Operating and Financial Results
May 09, 2024 07:00 ET | ProQR Therapeutics N.V.
Preclinical proof of concept data for the AX-0810 program targeting NTCP for cholestatic diseases presented at ASGCT 27th Annual Meeting – Management to host webinar today at 8:00 am EDT to highlight...
logo_ProQR-150x150.png
ProQR Nominates Martin Maier, PhD to Board and Announces Annual Meeting of Shareholders to be Held May 22, 2024
April 23, 2024 07:00 ET | ProQR Therapeutics N.V.
LEIDEN, Netherlands & CAMBRIDGE, Mass., April 23, 2024 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA...
logo_ProQR-150x150.png
ProQR Achieves Successful Defense of New Challenge to its Axiomer™ IP Portfolio
April 19, 2024 07:00 ET | ProQR Therapeutics N.V.
LEIDEN, Netherlands & CAMBRIDGE, Mass., April 19, 2024 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA...
logo_ProQR-150x150.png
ProQR Announces Year End 2023 Operating and Financial Results
March 13, 2024 07:00 ET | ProQR Therapeutics N.V.
Preclinical and translational pipeline program data for AX-0810 for Cholestatic Diseases targeting NTCP and AX-1412 for Cardiovascular Disease targeting B4GALT1 anticipated in 2024, building further...
logo_ProQR-150x150.png
ProQR Highlights New Platform Data from Presentation on Axiomer™ RNA Editing Technology at Deaminet 2024
January 19, 2024 07:00 ET | ProQR Therapeutics N.V.
Platform demonstrates robust in vivo editing capabilities reporting up to 70% editing of ACTB in the liver of non-human primates (NHPs) and miceFunctional effect demonstrated in mice in vivo via...
logo_ProQR-150x150.png
ProQR and Rett Syndrome Research Trust Join Forces with Axiomer™ RNA Editing Collaboration
January 05, 2024 07:00 ET | ProQR Therapeutics N.V.
Partnership focused on utilizing Axiomer™ to develop editing oligonucleotides targeting an underlying genetic variant that causes Rett syndromeCollaboration expands ProQR’s commitment to advance the...
logo_ProQR-150x150.png
ProQR Therapeutics Announces Transaction Completed for Théa to Acquire Sepofarsen and Ultevursen Ophthalmic Assets
December 08, 2023 07:30 ET | ProQR Therapeutics N.V.
Divestment of sepofarsen and ultevursen completed – Théa to continue development of sepofarsen and ultevursen for patients with LCA10 and Usher syndrome Agreement provides ProQR with initial payment...